Genmab shares rise 9% on positive Phase 3 clinical trial results for ovarian cancer treatment
GMAB Genmab ADR
$43.79 +9.48%
View chart & analysis → - 1Genmab announced positive topline results from the Phase 3 RAINFOL-02 trial of Rina-S (rinatabart sesutecan) for patients with platinum-resistant ovarian cancer.
- 2Rina-S recorded a 71% reduction in the risk of disease progression or death compared to standard chemotherapy.
- 3Shares of Concept Therapeutics fell 11%.
So what's the key point?
Genmab achieved positive results in an ovarian cancer treatment trial, showing a 71% reduction in the risk of disease progression or death. Genmab's stock price rose 9% following this news.
Source Investing.com +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.